A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer

LESSONS LEARNED. The combination of everolimus and low‐dose prednisone administered daily was hypothesized to prevent noninfectious pneumonitis (NIP) and mucositis, two common adverse events related to everolimus. Although mucositis was detected in only one case, all‐grade NIP occurred in four of ei...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncologist
Main Authors: Lolli, Cristian, Gallà, Valentina, Schepisi, Giuseppe, Barone, Domenico, Burgio, Salvatore Luca, Maugeri, Antonio, Vertogen, Bernadette, Amadori, Dino, De Giorgi, Ugo
Format: Artigo
Jezik:Inglês
Izdano: AlphaMed Press 2017
Teme:
Clinical Trial Results
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC5507652/
https://ncbi.nlm.nih.gov/pubmed/28546463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0154
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki